<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273947</url>
  </required_header>
  <id_info>
    <org_study_id>206221</org_study_id>
    <nct_id>NCT02273947</nct_id>
  </id_info>
  <brief_title>Food Effect Study With BMS-955176</brief_title>
  <official_title>An Open-Label, Randomized, Crossover Adaptive Design Study to Assess the Effect of Food on the Pharmacokinetics of BMS-955176 Administered as a Micronized Crystalline Tablet in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of a light meal, a standard meal, and a
      high fat meal on the PK of BMS-955176 MC tablet at a dose of 180 mg, relative to fasted
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose

      Other: This study will assess the impact of a light meal, a standard meal, and a high fat
      meal on the pharmacokinetics (PK) of BMS-955176 micronized crystalline (MC) tablet at a dose
      of 180 mg relative to fasted conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2014</start_date>
  <completion_date type="Actual">August 15, 2016</completion_date>
  <primary_completion_date type="Actual">August 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for BMS-955176</measure>
    <time_frame>Up to Day 4 of Period 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] for BMS-955176</measure>
    <time_frame>Up to Day 4 of Period 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] for BMS-955176</measure>
    <time_frame>Up to Day 4 of Period 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration at 24 hours post-dose (C24) for BMS-955176</measure>
    <time_frame>Up to Day 4 of Period 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 30 days post discontinuation of dosing</time_frame>
    <description>Safety and tolerability measured by incidence of AEs, serious AEs (SAEs), AEs leading to discontinuation and death, marked abnormalities in clinical laboratory tests, viral sign measurements, ECGs, and physical examination Adverse Events (AEs), Electrocardiogram (ECG)</description>
  </secondary_outcome>
  <number_of_arms>21</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Arm 1 (ABDC): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (BCAD): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (CDBA): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (DACB): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 (EFHG): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 (FGEH): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 (GHFE): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 (HEGF): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9 (IJK): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10 (JKI): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 11 (KIJ): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 12 (IKJ): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 13 (JIK): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 14 (KJI): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 15 (LMN): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 16 (OPQ): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 17 (PQO): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 18 (QOP): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 19 (OQP): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 20 (POQ): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 21 (QPO): BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 single dose by mouth for each treatment specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-955176</intervention_name>
    <description>Single dose by mouth for each treatment specified</description>
    <arm_group_label>Arm 9 (IJK): BMS-955176</arm_group_label>
    <arm_group_label>Arm 16 (OPQ): BMS-955176</arm_group_label>
    <arm_group_label>Arm 17 (PQO): BMS-955176</arm_group_label>
    <arm_group_label>Arm 11 (KIJ): BMS-955176</arm_group_label>
    <arm_group_label>Arm 5 (EFHG): BMS-955176</arm_group_label>
    <arm_group_label>Arm 15 (LMN): BMS-955176</arm_group_label>
    <arm_group_label>Arm 2 (BCAD): BMS-955176</arm_group_label>
    <arm_group_label>Arm 4 (DACB): BMS-955176</arm_group_label>
    <arm_group_label>Arm 14 (KJI): BMS-955176</arm_group_label>
    <arm_group_label>Arm 20 (POQ): BMS-955176</arm_group_label>
    <arm_group_label>Arm 19 (OQP): BMS-955176</arm_group_label>
    <arm_group_label>Arm 12 (IKJ): BMS-955176</arm_group_label>
    <arm_group_label>Arm 6 (FGEH): BMS-955176</arm_group_label>
    <arm_group_label>Arm 21 (QPO): BMS-955176</arm_group_label>
    <arm_group_label>Arm 10 (JKI): BMS-955176</arm_group_label>
    <arm_group_label>Arm 3 (CDBA): BMS-955176</arm_group_label>
    <arm_group_label>Arm 8 (HEGF): BMS-955176</arm_group_label>
    <arm_group_label>Arm 1 (ABDC): BMS-955176</arm_group_label>
    <arm_group_label>Arm 18 (QOP): BMS-955176</arm_group_label>
    <arm_group_label>Arm 13 (JIK): BMS-955176</arm_group_label>
    <arm_group_label>Arm 7 (GHFE): BMS-955176</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examinations, vital sign measurements, 12-lead ECG
             measurements, and clinical laboratory test results

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg)/[Height
             (m)]2

          -  Men and women, ages 18 to 50 years, inclusive

          -  Women must not be of childbearing potential, must not be breastfeeding

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of cardiac disease or clinically significant cardiac arrhythmias

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  Any major surgery within 4 weeks of study drug administration

          -  Any gastrointestinal surgery (including cholecystectomy) that could impact upon the
             absorption of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruddington Fields</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

